434960-42-6

Basic information

• Product Name: 5-bromo-6-fluoro-1H-indole
• Synonyms: 5-bromo-6-fluoro-1H-indole;5-Bromo-6-fluoro indole
• CAS NO: 434960-42-6
• Molecular Formula: C₈H₅BrFN
• Molecular Weight: 214.0344032
• Mol File: 434960-42-6.mol

Chemical Properties

• Boiling Point: 315.9±22.0 °C(Predicted)
• Appearance: /
• Density: 1.750±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 15.44±0.30(Predicted)
• CAS DataBase Reference: 5-bromo-6-fluoro-1H-indole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-6-fluoro-1H-indole(434960-42-6)
• EPA Substance Registry System: 5-bromo-6-fluoro-1H-indole(434960-42-6)

Safety Data

• Hazardous Substances Data: 434960-42-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-6-fluoro-1H-indole is used as a pharmaceutical intermediate for the synthesis of complex molecules and drug development. Its unique structure and properties make it a valuable building block in the creation of new pharmaceutical compounds.
Used in Material Science:
In the field of material science, 5-bromo-6-fluoro-1H-indole is utilized for the synthesis of more complex molecules and the development of advanced materials. Its specific reactions and behavior contribute to the design and properties of these materials.
It is important to handle 5-bromo-6-fluoro-1H-indole with caution and follow safety guidelines, as its health effects have not been fully studied.

Upstream product

• 1219741-80-6 4-bromo-5-fluoro-2-[(trimethylsilyl)ethynyl]aniline 
• 372-19-0 meta-fluoroaniline 
• 351-30-4 N-(4-bromo-3-fluorophenyl)ethanamide 
• 351-28-0 N-(3-fluorophenyl)acetamide 
• 1219741-79-3 4-bromo-5-fluoro-2-iodoaniline 
• 656-65-5 3-fluoro-4-bromophenylamine 

Downstream Products

• 1467057-27-7 6-fluoro-5-(4-(1-hydroxycyclobutyl)phenyl)-1H-indole-3-carboxylic acid 
• 1638759-63-3 methyl 5-bromo-6-fluoro-1H-indole-3-carboxylate 
• 1427358-21-1 6-fluoro-1H-indole-5-carbonitrile 
• 1589004-60-3 C₁₄H₉BrFNO₂S 

Relevant articles and documents

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

TRICYCLIC SULFONAMIDE DERIVATIVES

The invention relates to derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of pain.

TRICYCLIC SULFONAMIDE DERIVATIVES

The invention relates to derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of pain.

SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS

The present invention provides a new class of bicyclic heteroaryl compounds represented by Formula (I), pharmaceutical compositions containing these compounds, and their use for modulating the activity of GPR119 in the treatment of metabolic disorders and complications thereof, as well as methods for the treatment of the metabolic disorders and complications thereof.

Positive allosteric modulators of nicotinic acetylcholine receptor

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.

NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.